Total Payments
$316,111
2024 Payments
$30,136
Companies
27
Transactions
302
Medicare Patients
666
Medicare Billing
$237,894
Payment Breakdown by Category
Consulting$182,671 (57.8%)
Travel$49,965 (15.8%)
Other$49,388 (15.6%)
Research$27,886 (8.8%)
Food & Beverage$6,194 (2.0%)
Education$5.56 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $182,671 | 66 | 57.8% |
| Travel and Lodging | $49,965 | 58 | 15.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $33,316 | 25 | 10.5% |
| Unspecified | $27,886 | 40 | 8.8% |
| Honoraria | $16,073 | 5 | 5.1% |
| Food and Beverage | $6,194 | 107 | 2.0% |
| Education | $5.56 | 1 | 0.0% |
Payments by Type
General
$288,225
262 transactions
Research
$27,886
40 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $33,517 | 48 | $0 (2024) |
| Seagen Inc. | $32,169 | 15 | $0 (2023) |
| Merck Sharp & Dohme LLC | $30,625 | 36 | $0 (2022) |
| Astellas Pharma Global Development | $27,804 | 33 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $27,361 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $20,119 | 26 | $0 (2024) |
| Seattle Genetics, Inc. | $17,511 | 19 | $0 (2019) |
| PFIZER INC. | $17,425 | 16 | $0 (2024) |
| F. Hoffmann-La Roche AG | $17,414 | 23 | $0 (2020) |
| Chugai Pharmaceutical Co., Ltd. | $12,129 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,136 | 35 | PFIZER INC. ($15,298) |
| 2023 | $14,156 | 22 | AstraZeneca Pharmaceuticals LP ($3,464) |
| 2022 | $46,065 | 22 | Seagen Inc. ($18,898) |
| 2021 | $37,923 | 27 | Astellas Pharma Global Development ($15,116) |
| 2020 | $26,391 | 30 | Astellas Pharma Global Development ($6,103) |
| 2019 | $31,306 | 45 | Seattle Genetics, Inc. ($11,856) |
| 2018 | $86,088 | 75 | Bayer HealthCare Pharmaceuticals Inc. ($20,766) |
| 2017 | $44,046 | 46 | Merck Sharp & Dohme Corporation ($14,635) |
All Payment Transactions
302 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,773.40 | General |
| 11/18/2024 | EMD Serono Research & Development Institute, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 11/12/2024 | PFIZER INC. | PADCEV (Biological) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: Oncology | ||||||
| 10/15/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| 10/08/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: ONC | ||||||
| 10/01/2024 | PFIZER INC. | PADCEV (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,520.00 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 09/15/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 09/15/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $49.58 | General |
| Category: Oncology | ||||||
| 09/15/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $25.52 | General |
| 09/13/2024 | PFIZER INC. | PADCEV (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: PADCEV CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 08/28/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| 07/04/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| 07/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,487.50 | General |
| 06/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 06/19/2024 | PFIZER INC. | PADCEV (Biological) | Honoraria | Cash or cash equivalent | $3,437.50 | General |
| Category: Oncology | ||||||
| 06/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $305.66 | General |
| Category: ONC | ||||||
| 06/05/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $960.00 | General |
| Category: ONC | ||||||
| 06/03/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $192.50 | General |
| 06/03/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $7.35 | General |
| 06/02/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $35.81 | General |
| Category: ONC | ||||||
| 05/31/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 05/31/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $71.24 | General |
| Category: Oncology | ||||||
| 05/31/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $39.11 | General |
| Category: Oncology | ||||||
| 05/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $85.33 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | Astellas Pharma Global Development | $13,256 | 18 |
| AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY TO EVALUATE ENFORTUMAB VEDOTIN VS CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (EV-301) | Astellas Pharma Global Development | $4,916 | 4 |
| PCYC-1128-CA | Pharmacyclics LLC, An AbbVie Company | $3,480 | 3 |
| Bladder Cancer, Bladder Cancer and Safety Study of Atezolizumab in Bladder Cancer | F. Hoffmann-La Roche AG | $1,004 | 1 |
| NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| PADCEV CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF ASG-22CE GIVEN AS MONOTHERAPY IN SUBJECTS WITH METASTATIC UROTHELIAL CANCER AND OTHER MALIGNANT SOLID TUMORS THAT EXPRESS NECTIN-4 | Astellas Pharma Global Development | $852.50 | 1 |
| Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4 | Astellas Pharma Global Development | $818.74 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $554.41 | 1 |
| A Phase II, Multicentre, Single-Arm Study of Atezolizumab in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer, A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY IMvigor211, AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB | F. Hoffmann-La Roche AG | $438.46 | 1 |
| ASP1941 Phase II Clinical Study A Double-blind, Placebo-controlled, Parallel-group, Dose-response Study in Patients with Type 2 Diabetes Mellitus | Astellas Pharma Global Development | $333.84 | 3 |
| An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) | Astellas Pharma Global Development | $162.14 | 2 |
| A Phase II, Multicentre, Single-Arm Study of Atezolizumab in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer, A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY IMvigor211, A Phase II, Randomized Study of Atezolizumab Anti-PD-L1 Antibody | F. Hoffmann-La Roche AG | $161.59 | 1 |
| A Phase II, Multicentre, Single-Arm Study of Atezolizumab in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer, A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY IMvigor211 | F. Hoffmann-La Roche AG | $14.38 | 1 |
| Bladder Cancer and Bladder Cancer | F. Hoffmann-La Roche AG | $12.95 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 153 | 560 | $389,095 | $64,878 |
| 2022 | 3 | 160 | 533 | $366,155 | $63,808 |
| 2021 | 3 | 146 | 534 | $348,105 | $61,739 |
| 2020 | 7 | 207 | 631 | $319,480 | $47,469 |
Total Patients
666
Total Services
2,258
Medicare Billing
$237,894
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 67 | 367 | $267,910 | $46,114 | 17.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 54 | 161 | $87,745 | $13,607 | 15.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $33,440 | $5,156 | 15.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 62 | 306 | $226,440 | $41,049 | 18.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 66 | 195 | $106,275 | $17,294 | 16.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $33,440 | $5,466 | 16.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 54 | 249 | $179,280 | $33,736 | 18.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 65 | 258 | $140,610 | $23,312 | 16.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 27 | 27 | $28,215 | $4,691 | 16.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 61 | 270 | $140,400 | $19,440 | 13.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 41 | 148 | $102,120 | $14,656 | 14.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 16 | 57 | $28,215 | $5,519 | 19.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 46 | 93 | $33,015 | $4,464 | 13.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 20 | 34 | $4,930 | $1,614 | 32.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 11 | 11 | $8,885 | $1,340 | 15.1% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 12 | 18 | $1,915 | $435.82 | 22.8% |
About Dr. Jonathan Rosenberg, MD
Dr. Jonathan Rosenberg, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942268073.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Rosenberg, MD has received a total of $316,111 in payments from pharmaceutical and medical device companies, with $30,136 received in 2024. These payments were reported across 302 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($182,671).
As a Medicare-enrolled provider, Rosenberg has provided services to 666 Medicare beneficiaries, totaling 2,258 services with total Medicare billing of $237,894. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Medical Oncology
- Location New York, NY
- Active Since 05/01/2006
- Last Updated 10/09/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1942268073
Products in Payments
- TECENTRIQ (Biological) $43,238
- PADCEV (Biological) $30,151
- PADCEV (Drug) $21,219
- OPDIVO (Biological) $16,462
- IMFINZI (Drug) $10,286
- Trodelvy (Drug) $8,604
- Padcev (Drug) $8,042
- Bavencio (Drug) $7,365
- ASG22 (Biological) $5,655
- FYARRO (Drug) $3,600
- Ibrutinib (Drug) $3,480
- BALVERSA (Drug) $3,269
- BAVENCIO (Drug) $2,000
- Tecentriq (Biological) $1,632
- Cresemba (Drug) $818.74
- BGJ398 (Drug) $554.41
- LYNPARZA (Drug) $107.44
- Non-Covered Product (Drug) $60.00
- KEYTRUDA (Biological) $43.50
- Cabometyx (Drug) $29.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M